Biofabrication of small diameter tissue-engineered vascular grafts. (15th January 2022)

• Record Type: Journal Article
• Authors: Weekes, Angus; Bartnikowski, Nicole; Pinto, Nigel; Jenkins, Jason; Meinert, Christoph; Klein, Travis J.
• Is Part Of: Acta biomaterialia. Volume 138(2022)
• Page Start: 92
• Page End: 111
• Publication Date: 2022-01-15
• Subjects: Biofabrication -- Biomimetics -- Cardiovascular disease -- Regenerative medicine -- Tissue engineering -- Vascular graft bypassing; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2021.11.012
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Current clinical treatment strategies for the bypassing of small diameter (<6 mm) blood vessels in the management of cardiovascular disease frequently fail due to a lack of suitable autologous grafts, as well as infection, thrombosis, and intimal hyperplasia associated with synthetic grafts. The rapid advancement of 3D printing and regenerative medicine technologies enabling the manufacture of biological, tissue-engineered vascular grafts (TEVGs) with the ability to integrate, remodel, and repair in vivo, promises a paradigm shift in cardiovascular disease management. This review comprehensively covers current state-of-the-art biofabrication technologies for the development of biomimetic TEVGs. Various scaffold based additive manufacturing methods used in vascular tissue engineering, including 3D printing, bioprinting, electrospinning and melt electrowriting, are discussed and assessed against the biomechanical and functional requirements of human vasculature, while the efficacy of decellularization protocols currently applied to engineered and native vessels are evaluated. Further, we provide interdisciplinary insight into the outlook of regenerative medicine for the development of vascular grafts, exploring key considerations and perspectives for the successful clinical integration of evolving technologies. It is expected that continued advancements in microscale additive manufacturing, biofabrication, tissue engineering and decellularization will culminate in the development of clinically viable, off-the-shelf TEVGs for small diameter applications in the near future. Statement of significance: Current clinical strategies for the management of cardiovascular disease using small diameter vessel bypassing procedures are inadequate, with up to 75% of synthetic grafts failing within 3 years of implantation. It is this critically important clinical problem that researchers in the field of vascular tissue engineering and regenerative medicine aim to alleviate using biofabrication methods combining additive manufacturing, biomaterials science and advanced cellular biology. While many approaches facilitate the development of bioengineered constructs which mimic the structure and function of native blood vessels, several challenges must still be overcome for clinical translation of the next generation of tissue-engineered vascular grafts. Graphical abstract: Image, graphical abstract